Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported that its investigational gene therapy UX111 demonstrated sustained cognitive improvements and significant biomarker gains in long-term follow-up from two…
February 09, 2026
Roivant Sciences (NASDAQ: ROIV) shares jumped 15% on Thursday after the company announced highly encouraging Phase 2 trial results for brepocitinib in the treatment of…
February 06, 2026
Novo Nordisk Shares Rebound After FDA Signals Continued Support for GLP-1 Approvals
Novo Nordisk (NYSE: NVO) shares recovered Thursday following remarks from the U.S. Food and Drug Administration that reiterated support for ongoing and upcoming obesity and…
Eikon Therapeutics priced an upsized initial public offering, raising $381 million in new capital as it transitions from heavily venture-backed startup to publicly traded biotech….
February 04, 2026
Eli Lilly Raises Outlook as Obesity Drugs Power Strong Q4 Results
Eli Lilly and Company (NYSE: LLY) delivered a strong fourth-quarter performance and issued upbeat guidance, driven by continued momentum in its fast-growing obesity and diabetes…
February 02, 2026
MoonLake Immunotherapeutics Gains FDA Fast Track Designation for Sonelokimab in PPP
MoonLake Immunotherapeutics (NASDAQ: MLTX) jumped about 6.5% in premarket trading after the FDA granted Fast Track designation for the company’s sonelokimab (SLK) program in moderate-to-severe…
January 30, 2026
MediciNova Reaches 100-Patient Milestone in Expanded Access Program for ALS Treatment
MediciNova (NASDAQ: MNOV) announced that 100 patients with amyotrophic lateral sclerosis (ALS) have now been enrolled in its SEANOBI Expanded Access Program (EAP) evaluating MN-166…
Eli Lilly and Company (NYSE: LLY) has expanded its genetic medicine strategy with a new collaboration and licensing agreement valued at up to $1.12 billion…
A regulatory setback for REGENXBIO (NASDAQ: RGNX) is reshaping the competitive landscape in Hunter syndrome (MPS II), potentially giving Denali Therapeutics (NASDAQ: DNLI) a timing…
January 28, 2026
Immix Biopharma Secures Pivotal FDA Breakthrough Status
Immix Biopharma (NASDAQ: IMMX) recently secured a strategic regulatory win that has significantly altered the company’s investment profile. The company announced that the FDA granted…
OKYO Pharma (NASDAQ: OKYO) reported a successful Type C meeting with the U.S. Food and Drug Administration, marking an important regulatory milestone for its lead…
January 28, 2026
GRI Bio Stock Surges After Promising Gene Data on IPF Drug
GRI Bio Inc (NASDAQ:GRI) saw its stock gain by 37.6% in premarket trading on Wednesday. The surge followed the release of new data from its…